SCHEMBL5445797

SCHEMBL5445797

O=C(c1ccc2[nH]c3c(c2c1)CCCC3NC1CCCCC1)N1CCCC1

nearest known ligand 0.57

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
RB1 P06400 6/20 0.57
PARP1 P09874 4/20 0.49
SMN1; SMN2 Q16637 4/20 0.49
MAPT P10636 4/20 0.49
ALOX15 P16050 2/20 0.49
MAPK1 P28482 1/20 0.49
RAB9A P51151 2/20 0.49
NPC1 O15118 1/20 0.49
GFER P55789 1/20 0.49
BRD3 Q15059 2/20 0.47
MEN1 O00255 1/20 0.46
GLA P06280 1/20 0.46
KMT2A Q03164 1/20 0.46
CNR1 P21554 1/20 0.46
CNR2 P34972 1/20 0.45
ALDH1A1 P00352 2/20 0.43
LMNA P02545 1/20 0.43
POLB P06746 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5461711 1.00 RB1 (0.57) RB1PARP1SMN1; SMN2MAPTALOX15
SCHEMBL5459901 0.92 RB1 (0.53) RB1PARP1SMN1; SMN2MAPTALOX15
SCHEMBL5456645 0.92 RB1 (0.53) RB1PARP1SMN1; SMN2MAPTALOX15
SCHEMBL5454070 0.86 RB1 (0.63) RB1SMN1; SMN2MAPTALOX15MAPK1
SCHEMBL5467992 0.85 RB1 (0.62) RB1SMN1; SMN2MAPTALOX15MAPK1
SCHEMBL5449883 0.84 RB1 (0.61) RB1SMN1; SMN2MAPTALOX15MAPK1
SCHEMBL5449868 0.83 RB1 (0.60) RB1PARP1SMN1; SMN2MAPTALOX15
SCHEMBL5459696 0.83 RB1 (0.60) RB1SMN1; SMN2MAPTALOX15MAPK1
SCHEMBL5458980 0.82 RB1 (0.58) RB1SMN1; SMN2MAPTALOX15MAPK1
SCHEMBL5450266 0.82 PARP1 (0.56) RB1PARP1MAPTKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070276009-A1 Compositions and Methods for Viral Inhibition CHIRON CORPORATION 2007-11-29 US disclosed
US-20070276009-A1 Compositions and Methods for Viral Inhibition CHIRON CORPORATION 2007-11-29 US disclosed
US-20070276009-A1 Compositions and Methods for Viral Inhibition CHIRON CORPORATION 2007-11-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070276009-A1 Compositions and Methods for Viral Inhibition MAVS, SARS1, ZC3HAV1 RB1 1821/4885PARP1 709/4885SMN1; SMN2 4824/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.